Policy Research & Analysis
Some of the co-owners of Baird’s CMC have worked on policy issues in HIV since the early 1980s, on family planning since the 1970s and on women’s health issues over the same forty-year period.
Several now serve on boards of major international donors and implementers. Our partners have similarly impressive experience from work in foundations, governments and pharmaceutical companies.
That makes us uniquely well-positioned to tackle the toughest and most subtle policy issues.
What we’ve done
- A 47-country study of health and research priorities in sub-Saharan Africa for the European and Developing Country Clinical Trials Partnership, an agency of the European Commission. One of the focus areas was HIV
- A study on likely future policy on HPV vaccination in India for a major vaccine developer
- Two rounds of work for the Johns Hopkins Bloomberg School of Public Health on the reasons why vaccines — including hepatitis B — have or have not been adopted in low-income countries
- Identification of the 200 most influential people in the world on HIV policy, how they interacted and which led which areas of discussion. The project included organising independent expert review and validation of our findings
- In-depth research for Gavi on the opportunities for new donor funding from the BRICS countries and the Middle East. One of the Gavi initiatives discussed was immunisation against HPV and the prevention of cervical cancer
- A project for the Department of Science and Technology of the Republic of South Africa on the future of the country’s HIV vaccine research programme
- A continuing project on India’s likely approach to access to medicines and to purchasing, pricing and intellectual property. We also look at interactions with civil society. Clients for this work have included PhRMA, major pharmaceutical companies and NGOs